RegeneRx Biopharmaceuticals, Inc.
RGRX · OTC
3/31/2023 | 12/31/2022 | 9/30/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Market Cap | $1,506,750 | $1,993,910 | $2,009,700 | $2,225,025 |
| - Cash | $102 | $291 | $478 | $707 |
| + Debt | $1,495 | $1,446 | $1,389 | $1,258 |
| Enterprise Value | $1,508,143 | $1,995,065 | $2,010,610 | $2,225,576 |
| Revenue | $19 | $19 | $19 | $19 |
| % Growth | 0% | 0% | -0% | – |
| Gross Profit | $19 | $19 | $19 | $19 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$305 | -$0 | $0 | -$0 |
| % Margin | -1,589.3% | -0.8% | 2.4% | -0.8% |
| Net Income | -$385 | -$391 | -$366 | -$546 |
| % Margin | -2,006.3% | -2,037.5% | -1,907.2% | -2,845.1% |
| EPS Diluted | -0.003 | -0.003 | -0.003 | -0.004 |
| % Growth | 0% | -3.8% | 31.6% | – |
| Operating Cash Flow | -$189 | -$188 | -$228 | -$219 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$189 | -$188 | -$228 | -$219 |